Solid Biosciences (NASDAQ:SLDB) versus Atyr PHARMA (NASDAQ:ATYR) Head to Head Comparison

Atyr PHARMA (NASDAQ:ATYR) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Volatility and Risk

Atyr PHARMA has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500.

Valuation & Earnings

This table compares Atyr PHARMA and Solid Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atyr PHARMA	$235,000.00	1,312.09	-$50.39 million	($0.87)	-3.99
Solid Biosciences	$8.09 million	32.86	-$96.01 million	($3.04)	-1.13

Atyr PHARMA has higher earnings, but lower revenue than Solid Biosciences. Atyr PHARMA is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Atyr PHARMA and Solid Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atyr PHARMA	N/A	-79.44%	-59.16%
Solid Biosciences	N/A	-58.75%	-47.84%

Insider & Institutional Ownership

61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 13.6% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Atyr PHARMA and Solid Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atyr PHARMA	0	0	6	1	3.14
Solid Biosciences	0	0	8	4	3.33

Atyr PHARMA presently has a consensus target price of $18.60, indicating a potential upside of 436.02%. Solid Biosciences has a consensus target price of $15.67, indicating a potential upside of 356.75%. Given Atyr PHARMA’s higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than Solid Biosciences.

Summary

Solid Biosciences beats Atyr PHARMA on 10 of the 14 factors compared between the two stocks.

About Atyr PHARMA

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

About Solid Biosciences

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.